Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis

Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis

Immunotherapy based on anti PD-1/PD-L1 inhibitors is the new standard of advanced non-small cell lung cancers. Pembrolizumab, nivolumab and atezolizumab are used in clinical practice. The strict eligibility criteria of clinical trials do not allow researchers to fully represent treatment effects in...

Full description

Bibliographic Details
Main Authors: Manlio Mencoboni, Marcello Ceppi, Marco Bruzzone, Paola Taveggia, Alessia Cavo, Francesca Scordamaglia, Marina Gualco, Rosa Angela Filiberti
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
non-small cell lung cancer
NSCLC
immunotherapy
immune checkpoint inhibitors
nivolumab
pembrolizumab
Online Access:https://www.mdpi.com/2072-6694/13/6/1388

Internet

https://www.mdpi.com/2072-6694/13/6/1388

Similar Items